Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Gilead Sciences
Biotech
ASCO: Kite's CAR-T flies high in phase 1 B-cell lymphoma study
No grade 4 or 5 cases of cytokine release syndrome or immune effector cell-associated neurotoxicity syndrome occurred.
Gabrielle Masson
May 31, 2025 7:00pm
Gilead pays partner Hookipa $10M for HBV, HIV vaccines
May 22, 2025 10:10am
Galapagos gets cold feet over plans to split up company
May 13, 2025 6:55am
Gilead's accounting chief hits the exit—Chutes & Ladders
Mar 14, 2025 8:30am
Gilead loses interest in Arcus' rival to Merck's Welireg
Feb 18, 2025 8:19am
Gilead roars into JPM25 with $250M upfront deal for Leo
Jan 11, 2025 5:30pm
